Hematology/Oncology wRVU Compensation in 2026: Benchmarks, Chemotherapy Revenue, Infusion Margin, and What to Ask Before You Sign

Hematology/oncology compensation is structurally complex. The wRVU portion of compensation is significant — median $68/wRVU at 5,800 wRVUs annually — but the larger revenue engine for most hem/onc practices is the infusion suite. Chemotherapy administration, biologic immunotherapy, and other infusion-based treatments generate substantial buy-and-bill margin revenue that often dwarfs the wRVU compensation. Contract terms governing how that infusion revenue is distributed determine the actual financial structure of a hem/onc job.

If you are a hematologist/oncologist evaluating a contract — finishing fellowship, switching practices, or considering a private group versus academic versus hospital employment — here is what the 2026 market actually looks like and where the financial issues hide.

What the 2026 hematology/oncology benchmarks actually are

Based on MGMA 2025 data, the median hem/onc physician produces approximately 5,800 wRVUs annually at $68 per wRVU. Total compensation at the median runs $400,000-$460,000 in pure clinical roles. Hem/onc physicians in practices with substantial infusion revenue often exceed $600,000-$750,000.

The 75th percentile hem/onc physician produces around 7,500 wRVUs annually. The 90th percentile is 9,200.

The per-wRVU rate of $68 is among the higher cognitive specialty rates because oncology coding includes time-based chemotherapy oversight codes and infusion supervision that carry meaningful wRVU values.

Hematology/oncology is largely cognitive and not significantly affected by the 2026 CMS efficiency adjustment, though chemotherapy administration codes did see modest changes.

The three hem/onc contract traps

Chemotherapy infusion margin retained entirely by the practice. This is the biggest financial issue in hem/onc contracts. Chemotherapy and biologic infusions generate substantial drug margin revenue — the practice purchases drugs from the wholesaler at one price and bills the payer at a higher rate, capturing the spread. For an active oncologist with a moderate infusion patient panel, this margin can total $300,000-$1,200,000+ annually depending on the patient population and drug mix.

Many contracts retain this revenue entirely with the practice or hospital, paying the oncologist a base salary or wRVU bonus that does not reflect the infusion margin generated by their patients. Fair contract language addresses this — either the infusion margin flows to a bonus pool that includes the oncologist whose patients are infused, or the per-wRVU rate is elevated to capture a share.

Clinical trial enrollment metrics that quietly affect compensation. Many academic and large community hem/onc practices include clinical trial enrollment targets in compensation. These can be structured as quality metrics or as direct bonuses tied to trial accruals. Read the specific targets carefully — clinical trial enrollment is influenced by factors outside your control (trial availability, patient eligibility, sponsor decisions), and aggressive enrollment targets create pressure that may not match your patient panel.

Call coverage for inpatient oncology with no defined volume cap. Hospital-employed oncologists often face inpatient consultation and admit coverage as part of clinical responsibilities. Volumes can be heavy — particularly in centers with active leukemia, lymphoma, and BMT services. Many contracts handle inpatient coverage with vague language.

Fair contract language defines a maximum inpatient coverage frequency (commonly 4-8 weeks per year for outpatient-primary oncologists), addresses post-coverage outpatient relief, and provides separate compensation for high-volume coverage periods.

What fair hem/onc contract language looks like

On the wRVU structure: a threshold at or below the 50th percentile (around 5,800 wRVUs) with a rate at or above $68/wRVU.

On infusion revenue: explicit language ensuring chemotherapy and biologic infusion margin flows back to the oncologist either through a transparent revenue share or an elevated per-wRVU rate.

On clinical trial enrollment: realistic, defined targets that account for factors outside the physician's control.

On inpatient coverage: a defined maximum coverage frequency with post-coverage outpatient relief and separate compensation for high-volume periods.

What to ask before you sign

Four specific questions worth getting answered in writing before you commit to a hem/onc contract:

1. What happens with chemotherapy and biologic infusion margin revenue from drugs administered to my patients — does it flow back to me through a revenue share, an elevated per-wRVU rate, or is it retained entirely by the practice or hospital?
2. What are the clinical trial enrollment targets (if any), and how were those targets set relative to trial availability and patient panel realities?
3. What is the maximum inpatient coverage frequency I will be assigned, is there post-coverage outpatient relief, and is there separate compensation for high-volume periods?
4. What was the average total compensation paid to hem/onc physicians at the practice over the past 3 years, including infusion revenue distributions?

These are reasonable questions. Vague answers on infusion margin, trial targets, or coverage structure tell you exactly how the math will work in practice.

Want to know how your specific hematology/oncology contract compares to these benchmarks? FairRVU runs the full analysis in 60 seconds — wRVU threshold percentile, infusion revenue distribution analysis, trial enrollment review, and inpatient coverage evaluation. Your contract is permanently deleted after processing.